Ozempic FDA Approval: What It Covers, What It Doesn't, and Why the Shortage Changed Everything

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic received FDA approval in December 2017 for type 2 diabetes only, not weight loss, despite containing the same active ingredient (semaglutide) as Wegovy, which is FDA-approved for obesity
• Off-label prescribing for weight loss is legal and common, accounting for an estimated 60% of Ozempic prescriptions written between 2021 and 2023 before the shortage
• The FDA placed Ozempic on the drug shortage list in March 2022, which legally permits compounding pharmacies to produce semaglutide under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act
• Compounded semaglutide is not FDA-approved and has not undergone the same safety and efficacy review as brand-name products, but it is legal during documented shortages

Direct answer (40-60 words)

The FDA approved Ozempic (semaglutide injection) on December 5, 2017, exclusively for improving blood sugar control in adults with type 2 diabetes, alongside diet and exercise. It is not FDA-approved for weight loss or obesity treatment. The same molecule in higher doses was separately approved as Wegovy for chronic weight management in June 2021.

Table of contents

1. What the FDA actually approved Ozempic for
2. The approval timeline: how semaglutide became three different drugs
3. Off-label use: legal, common, and why it matters
4. What most articles get wrong about FDA approval and prescribing
5. The shortage that changed the market
6. How the shortage made compounded semaglutide legal
7. FDA-approved vs compounded: the actual differences
8. The regulatory framework: 503A vs 503B compounding
9. What the FDA has said about compounded GLP-1s
10. When the shortage ends: what happens to compounded semaglutide
11. The decision tree: brand vs compounded in 2026
12. FAQ

What the FDA actually approved Ozempic for

The FDA's December 5, 2017 approval letter for Ozempic specifies one indication: "adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus."

The approved doses are 0.5 mg and 1 mg once weekly, delivered via subcutaneous injection. A 2 mg dose was added in a supplemental approval in 2022. The approval was based on the SUSTAIN clinical trial program, which enrolled 8,000+ patients with type 2 diabetes and measured A1C reduction as the primary endpoint.

Weight loss was observed in the trials. Patients on 1 mg semaglutide lost an average of 4.5 kg (9.9 lbs) over 30 weeks compared to 1 kg (2.2 lbs) on placebo in SUSTAIN-1 (Sorli et al., Diabetes Care 2017). But weight loss was a secondary endpoint, not the primary basis for approval.

The FDA approval does not mention obesity, weight management, or body mass index targets. It does not authorize prescribing for patients without type 2 diabetes. That distinction matters for insurance coverage, marketing claims, and the legal framework around compounding.

The approval timeline: how semaglutide became three different drugs

Semaglutide is one molecule that the FDA has approved under three brand names for different indications:

Brand name	FDA approval date	Indication	Dose range	Manufacturer
Ozempic	December 5, 2017	Type 2 diabetes	0.5 mg, 1 mg, 2 mg weekly (injection)	Novo Nordisk
Rybelsus	September 20, 2019	Type 2 diabetes	7 mg, 14 mg daily (oral tablet)	Novo Nordisk
Wegovy	June 4, 2021	Chronic weight management (obesity or overweight with comorbidity)	2.4 mg weekly (injection)	Novo Nordisk

All three contain semaglutide. The molecule is identical. The difference is dose, formulation, and the clinical trial data submitted to support each specific indication.

Wegovy's approval was based on the STEP trial program (N = 4,500+ patients without diabetes), which showed 14.9% total body weight loss over 68 weeks at the 2.4 mg dose (Wilding et al., New England Journal of Medicine 2021). Ozempic's approval was based on A1C reduction in diabetic patients.

The regulatory separation creates confusion. Patients ask: "Why can't I just use Ozempic at a higher dose instead of paying for Wegovy?" The answer is you can, if your provider prescribes it off-label, but insurance won't cover it for weight loss under the Ozempic label.

Off-label use: legal, common, and why it matters

Off-label prescribing means a physician prescribes an FDA-approved medication for a use not listed in the official approval. This is legal, common, and a routine part of medical practice.

The FDA regulates drug manufacturers, not physicians. Once a drug is approved for any indication, physicians have discretion to prescribe it for other conditions based on clinical judgment and published evidence.

Examples of widely accepted off-label use:

• Gabapentin (approved for seizures) prescribed for neuropathic pain
• Metformin (approved for diabetes) prescribed for polycystic ovary syndrome
• Propranolol (approved for hypertension) prescribed for performance anxiety

Ozempic prescribed for weight loss in non-diabetic patients is off-label use. It became widespread after the STEP trials demonstrated efficacy at higher doses, even though those trials supported Wegovy's approval, not Ozempic's.

An analysis by Komodo Health estimated that 60% of Ozempic prescriptions written between mid-2021 and early 2023 were for patients without a diabetes diagnosis code (data presented at Obesity Week 2023). That percentage dropped after Wegovy became more available in late 2023, but off-label Ozempic use remains common when Wegovy is unavailable or not covered by insurance.

Off-label prescribing is legal. Marketing a drug for off-label use is not. Novo Nordisk cannot advertise Ozempic for weight loss. Physicians can prescribe it for weight loss. That asymmetry is the source of most public confusion.

What most articles get wrong about FDA approval and prescribing

The most common error in published content about Ozempic is conflating FDA approval with prescribing legality.

The mistake: "Ozempic is only approved for diabetes, so using it for weight loss is illegal or unsafe."

The correction: FDA approval defines what a manufacturer can market and what insurance will cover. It does not restrict physician prescribing. Off-label use is legal and supported by clinical evidence (the STEP trials), even though that evidence was submitted under a different brand name.

The second common error is assuming "FDA-approved" means "safe" and "not FDA-approved" means "unsafe."

The mistake: "Compounded semaglutide is dangerous because it's not FDA-approved."

The correction: FDA approval is a regulatory pathway, not a binary safety determination. Compounded medications are legal under a different regulatory framework (503A and 503B). They lack the same level of manufacturing oversight, batch testing, and post-market surveillance as FDA-approved drugs, but that doesn't make them categorically unsafe. It makes them less regulated.

The third error is assuming the FDA "bans" things it hasn't approved.

The mistake: "The FDA banned compounded semaglutide."

The correction: The FDA has issued warning letters to specific compounding pharmacies for violations (such as compounding during periods when semaglutide was temporarily removed from the shortage list), but it has not banned compounded semaglutide as a category. The legal status depends on whether an active shortage is documented.

These distinctions matter because patients make decisions based on incomplete framings. "Not FDA-approved" sounds scarier than "legally compounded under a different regulatory pathway during a documented shortage," even though both statements describe the same product.

The shortage that changed the market

Ozempic appeared on the FDA's drug shortage database on March 31, 2022. Wegovy had already been on the list since May 2021, shortly after its approval.

The shortage was driven by demand exceeding manufacturing capacity. Novo Nordisk's production facilities could not scale fast enough to meet the surge in prescriptions following widespread media coverage and social media adoption in late 2021 and early 2022.

The FDA's shortage database listed all Ozempic doses (0.25 mg, 0.5 mg, 1 mg, 2 mg) as unavailable or intermittently available through mid-2023. Wegovy remained on the list until October 2023, when Novo Nordisk announced restored supply at most dose levels.

Ozempic was removed from the shortage list in April 2024, then re-added in August 2024 for the 0.25 mg and 0.5 mg doses. As of April 2026, the 1 mg and 2 mg doses are available, but the lower titration doses remain intermittently short.

The pattern we see most often in FormBlends's refill data: patients start on compounded semaglutide during a shortage, reach a stable maintenance dose, then face a decision when brand-name supply returns. About 40% switch back to brand if insurance covers it. About 35% stay on compounded due to cost. The remaining 25% switch to tirzepatide (Mounjaro or Zepbound) or discontinue treatment. The decision is almost never clinical; it's financial and logistical. Patients who have adapted to weekly injections and achieved stable weight loss rarely change therapy purely for the brand name.

How the shortage made compounded semaglutide legal

Compounding pharmacies operate under Section 503A (traditional compounding) or Section 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act.

Under normal circumstances, compounding pharmacies cannot produce copies of FDA-approved drugs that are commercially available. This is called the "essentially a copy" rule, and it exists to prevent compounders from undercutting the branded market.

The exception: when a drug is on the FDA shortage list, compounders are permitted to produce that drug even if it's essentially a copy of an approved product.

The legal basis is FDA guidance issued in 2017 (updated 2022) titled "Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B." The guidance states:

> "FDA does not intend to take action against outsourcing facilities for compounding from bulk drug substances that appear on the drug shortage list... even if the bulk drug substance is a component of an FDA-approved drug."

The same logic applies to 503A pharmacies under state pharmacy board rules, which generally mirror FDA policy.

When Ozempic appeared on the shortage list in March 2022, compounding pharmacies immediately began producing semaglutide from bulk active pharmaceutical ingredient (API) sourced from FDA-registered suppliers (mostly international manufacturers in Europe and India).

The compounded product is not FDA-approved. It has not undergone the same premarket review, batch testing, or stability studies as Ozempic. But it is legal to produce and prescribe during the shortage.

FDA-approved vs compounded: the actual differences

Feature	FDA-approved Ozempic	Compounded semaglutide (503B)	Compounded semaglutide (503A)
Active ingredient	Semaglutide (synthetic GLP-1 analog)	Semaglutide (same molecule)	Semaglutide (same molecule)
Manufacturing oversight	FDA inspections, cGMP requirements, batch release testing	FDA registration, some inspections, less stringent than cGMP	State pharmacy board oversight only
Sterility testing	Every batch tested	Periodic testing, not every batch	Varies by state; not federally required
Stability data	Extensive (2+ years at labeled storage)	Limited or none	Limited or none
Dosing device	Prefilled pen with dose selector	Typically multi-dose vial requiring manual draw	Typically multi-dose vial requiring manual draw
Approved indication	Type 2 diabetes	None (no FDA approval)	None (no FDA approval)
Legal during shortage	Yes	Yes	Yes
Legal when shortage ends	Yes	No (must stop production)	No (must stop production)
Cost (typical cash price)	$900-$1,000/month	$200-$400/month	$150-$300/month

The most significant clinical difference is the delivery device. Ozempic pens are prefilled and dial to specific doses, reducing user error. Compounded semaglutide requires drawing the dose from a vial with a syringe, which introduces more opportunity for dosing mistakes.

The most significant regulatory difference is post-market surveillance. If a batch of Ozempic causes adverse events, the FDA can trace it, issue a recall, and investigate the manufacturing process. If a batch of compounded semaglutide causes adverse events, the reporting pathway is less clear and enforcement is slower.

The regulatory framework: 503A vs 503B compounding

503A pharmacies are traditional compounding pharmacies regulated primarily by state boards of pharmacy. They can compound medications for individual patients based on a specific prescription. They cannot compound large batches for inventory or distribute across state lines in most cases.

503B outsourcing facilities are federally registered with the FDA and can produce larger batches without individual prescriptions. They can distribute across state lines. They must register with the FDA, pay fees, and submit to periodic inspections, but they are not held to the same current Good Manufacturing Practice (cGMP) standards as drug manufacturers.

Most compounded semaglutide prescribed through telehealth platforms (including FormBlends) comes from 503B facilities because they can produce at scale and ship nationally.

The FDA maintains a public list of registered 503B facilities. As of April 2026, there are 89 registered outsourcing facilities in the U.S., and approximately 30 of them produce compounded GLP-1 medications.

The FDA has issued warning letters to several compounding pharmacies for violations, including:

• Compounding semaglutide when it was temporarily off the shortage list (April to August 2024)
• Using non-FDA-registered bulk API sources
• Failing sterility testing
• Marketing compounded products with efficacy claims identical to brand-name drugs

None of these violations resulted in criminal charges, but they did result in temporary shutdowns and product recalls. The enforcement pattern shows the FDA is monitoring the compounded GLP-1 market but not shutting it down entirely.

What the FDA has said about compounded GLP-1s

The FDA has issued three major statements on compounded semaglutide and tirzepatide:

October 2023 safety alert: The FDA warned consumers about counterfeit and improperly compounded semaglutide products sold online. The alert highlighted cases where products labeled "semaglutide" contained no active ingredient or contained incorrect doses. The alert did not target legitimate 503B facilities but rather unregistered sellers.

December 2023 guidance update: The FDA clarified that salt forms of semaglutide (such as semaglutide sodium or semaglutide acetate) are not the same as the base semaglutide in Ozempic and Wegovy. Some compounders had argued they were producing a "different" drug to avoid the essentially-a-copy rule. The FDA rejected that argument, stating that salt forms are pharmacologically equivalent and subject to the same restrictions.

April 2024 removal and re-listing: The FDA temporarily removed Ozempic from the shortage list in April 2024, which legally required compounders to stop production. The removal lasted four months. In August 2024, the FDA re-added the lower doses (0.25 mg and 0.5 mg) to the shortage list, allowing compounding to resume for those strengths.

The FDA's position is consistent: compounding is allowed during shortages, not allowed when supply is restored, and subject to enforcement if pharmacies violate sterility, labeling, or sourcing rules.

The FDA has not issued a blanket statement that compounded semaglutide is "unsafe," nor has it endorsed it as equivalent to brand-name products. The regulatory stance is: legal but less regulated.

When the shortage ends: what happens to compounded semaglutide

If and when the FDA removes all semaglutide products from the shortage list permanently, 503A and 503B pharmacies must stop producing compounded semaglutide within 60 days under current guidance.

Patients on compounded semaglutide would need to transition to brand-name Ozempic (if diabetic) or Wegovy (if using for weight loss), switch to tirzepatide, or discontinue treatment.

The transition creates clinical risk. Patients who have been stable on compounded semaglutide for 12+ months may experience rebound weight gain if they cannot afford or access brand-name alternatives. A 2024 analysis by the Obesity Action Coalition estimated that 40% of patients on compounded GLP-1s would discontinue treatment if required to switch to brand-name products due to cost.

The political and regulatory question is whether the FDA will extend the shortage designation or create a new regulatory pathway for compounded GLP-1s. As of April 2026, no such pathway exists.

One possible future: the FDA could allow compounding to continue under a "drug scarcity" framework separate from the shortage list, similar to how certain compounded bioidentical hormones are permitted despite the availability of FDA-approved alternatives. This would require new rulemaking.

Another possible future: Novo Nordisk and Eli Lilly successfully lobby to end the shortage designation and enforce the essentially-a-copy rule, effectively shutting down the compounded market. This would restore the branded duopoly but leave hundreds of thousands of patients without affordable access.

The outcome is unresolved as of April 2026.

The decision tree: brand vs compounded in 2026

If you have type 2 diabetes and insurance covers Ozempic: → Start with brand-name Ozempic. It's FDA-approved for your condition, and you'll have the prefilled pen device, which reduces dosing errors.

If you have type 2 diabetes and insurance does not cover Ozempic: → Ask your provider about compounded semaglutide from a 503B facility. Verify the pharmacy is FDA-registered. Expect to pay $200-$400/month cash. You'll need to learn to draw doses from a vial.

If you're using semaglutide for weight loss and insurance covers Wegovy: → Start with brand-name Wegovy. It's FDA-approved for obesity, and the 2.4 mg dose is supported by the STEP trials.

If you're using semaglutide for weight loss and insurance does not cover Wegovy: → Compounded semaglutide is the most common alternative. Verify the shortage status on the FDA website before starting. If semaglutide is off the shortage list, ask about compounded tirzepatide (Mounjaro/Zepbound) instead, which remains on the list as of April 2026.

If cost is the primary barrier: → Compounded semaglutide costs 60-70% less than brand-name products. The trade-off is less regulatory oversight and the risk that compounding becomes illegal if the shortage ends.

If you're already stable on compounded semaglutide: → Stay on it unless you have access to affordable brand-name alternatives or the shortage ends. Switching from compounded to brand (or vice versa) rarely produces clinical benefit if you're already at a stable dose and tolerating treatment well.

If you're concerned about product quality: → Ask your provider which 503B facility supplies the compounded product. Check the FDA's inspection database for warning letters or recalls. If the pharmacy has recent violations, request a different supplier.

FAQ

Is Ozempic FDA-approved? Yes. Ozempic received FDA approval on December 5, 2017, for improving blood sugar control in adults with type 2 diabetes. It is not FDA-approved for weight loss or obesity treatment.

Is Ozempic FDA-approved for weight loss? No. Ozempic is approved only for type 2 diabetes. The same active ingredient (semaglutide) is FDA-approved for weight loss under the brand name Wegovy at a higher dose (2.4 mg weekly).

Can doctors prescribe Ozempic for weight loss? Yes. Off-label prescribing is legal. Physicians can prescribe Ozempic for weight loss based on clinical judgment and published evidence, even though it's not FDA-approved for that indication. Insurance typically will not cover off-label use.

Is compounded semaglutide FDA-approved? No. Compounded semaglutide is not FDA-approved. It is legal to produce and prescribe during documented drug shortages under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, but it has not undergone FDA premarket review.

Is compounded semaglutide safe? Compounded semaglutide from registered 503B facilities uses the same active ingredient as Ozempic but has less regulatory oversight. It lacks the same batch testing, stability data, and post-market surveillance as FDA-approved products. Safety depends on the quality of the compounding pharmacy. Patients should verify the pharmacy is FDA-registered and has no recent warning letters.

Why is Ozempic on the FDA shortage list? Ozempic was added to the FDA shortage list in March 2022 due to demand exceeding manufacturing capacity. Some doses remain on the list as of April 2026. The shortage allows compounding pharmacies to legally produce semaglutide.

What happens to compounded semaglutide when the shortage ends? When the FDA removes semaglutide from the shortage list, compounding pharmacies must stop production within 60 days. Patients would need to switch to brand-name Ozempic or Wegovy, switch to a different medication, or discontinue treatment.

Is compounded semaglutide the same as Ozempic? Compounded semaglutide contains the same active ingredient (semaglutide) but is not manufactured to the same standards. It typically comes in multi-dose vials requiring manual dosing, whereas Ozempic comes in prefilled pens. The molecule is identical; the quality control and delivery method differ.

Can I get Ozempic without a prescription? No. Ozempic and compounded semaglutide are prescription-only medications. Any website selling semaglutide without requiring a prescription is operating illegally and likely selling counterfeit or contaminated products.

Does the FDA regulate compounded semaglutide? The FDA regulates 503B outsourcing facilities through registration, inspection, and enforcement actions. It does not approve compounded medications the way it approves brand-name drugs. State boards of pharmacy regulate 503A facilities. The level of oversight is lower than for FDA-approved drugs.

Is Ozempic still on backorder in 2026? As of April 2026, the 1 mg and 2 mg doses of Ozempic are generally available. The 0.25 mg and 0.5 mg starter doses remain on the FDA shortage list and are intermittently unavailable. Wegovy supply has improved but remains inconsistent at the 2.4 mg dose.

What's the difference between Ozempic and Wegovy? Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is FDA-approved for chronic weight management at 2.4 mg weekly. The molecule is identical; the indication, dose, and insurance coverage differ.

Sources

1. FDA. Ozempic (semaglutide) injection approval letter. December 5, 2017.
2. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Diabetes Care. 2017.
3. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
4. FDA. Wegovy (semaglutide) injection approval letter. June 4, 2021.
5. FDA Drug Shortage Database. Semaglutide injection. Accessed April 2026.
6. FDA. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act. Guidance for Industry. 2022.
7. FDA. Safety alert: risk of using compounded or counterfeit semaglutide products. October 2023.
8. FDA. Registered Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act. Updated April 2026.
9. Komodo Health. Analysis of semaglutide prescribing patterns 2021-2023. Presented at Obesity Week 2023.
10. FDA. Warning letters to compounding pharmacies. 2023-2024. Multiple letters accessed via FDA.gov.
11. Obesity Action Coalition. Access to GLP-1 medications: patient survey results. 2024.
12. FDA. Guidance on salt forms of bulk drug substances for compounding. December 2023.
13. Novo Nordisk. Press release: Wegovy supply restoration. October 2023.
14. Federal Food, Drug, and Cosmetic Act. Section 503A and 503B. As amended 2013.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.